<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Olaparib &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/olaparib/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 05 Oct 2026 15:57:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Olaparib &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Adding Bevacizumab to Olaparib Boosts Survival Only in BRCA-Mutated Ovarian Cancer</title>
		<link>https://bioengineer.org/adding-bevacizumab-to-olaparib-boosts-survival-only-in-brca-mutated-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 05 Oct 2026 15:57:42 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[anti-angiogenic therapy]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[Biomarker-driven therapy]]></category>
		<category><![CDATA[BRCA mutation]]></category>
		<category><![CDATA[high-grade serous ovarian carcinoma]]></category>
		<category><![CDATA[maintenance therapy]]></category>
		<category><![CDATA[Olaparib]]></category>
		<category><![CDATA[Ovarian cancer]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[PARP inhibitor]]></category>
		<category><![CDATA[progression-free survival]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=402814</guid>

					<description><![CDATA[A real-world study of 214 patients finds that adding Bevacizumab to Olaparib maintenance therapy significantly improves overall survival only in BRCA-mutated high-grade serous ovarian carcinoma, supporting biomarker-driven treatment selection.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">402814</post-id>	</item>
	</channel>
</rss>
